# lung adenocarcinoma (LUAD) - minimax-m3

- Benchmark system: raw
- Repeat: 3
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: MiniMax / minimax-m3
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 3468
- Completion tokens: 5935
- Reasoning tokens: 
- Total tokens: 9403
- API requests reported: 
- Elapsed seconds: 37.934
- Final benchmark system: raw; file rank 2/5; original repeat 3; model vendor: MiniMax

---
<think>The user wants me to perform a multidimensional, evidence-grounded interpretation of transcriptomic prognostic data for lung adenocarcinoma (LUAD). Let me carefully analyze the input.

Looking at the data, I notice something immediately problematic: the vast majority of genes have extremely large or infinite hazard ratios (HR = 5.18e+21, which is essentially infinity), and P values of exactly 0 with FDR of 0. This is statistically suspicious and likely represents data quality issues, possibly from:

1. Extreme outliers or sparse events causing numerical instability
2. Pseudogenes and unprocessed lncRNAs dominating the list
3. Possible numerical overflow in the Cox regression

The genes with extreme HRs are almost all:
- Pseudogenes (RBMY1F, RBMXP1, FAM9A, RAP1BP2, HMGN2P39, etc.)
- Y-chromosome or testis-specific genes (RBMY1F, RBMY2AP, FAM9A, CDY10P, USP9YP3, TTTY4C, TEX13A)
- lncRNAs with no clear functional annotation
- "UNMAPPED" entries
- Small ncRNA pseudogenes

This pattern strongly suggests **sex-linked artifacts** rather than true prognostic biology, because:
- Many genes are Y-chromosome located
- Female LUAD patients would have near-zero expression, creating bimodal distributions
- This would cause extreme HR estimates

The biologically interpretable genes are at the bottom:
- RBMXP1 (HR=0.21, protective) - pseudogene of RBMX
- PITX3 (HR=1.43, risk)
- DKK1 (HR=1.48, risk) - Wnt antagonist, known in cancer
- LINC01312 (HR=1.36, risk)
- VAX1 (HR=1.33, risk) - transcription factor
- TLE1 (HR=1.48, risk) - Wnt/Notch pathway
- CRNDE (HR=0.72, protective) - lncRNA
- KRT6A (HR=1.39, risk) - keratin
- FUT4 (HR=1.40, risk) - fucosyltransferase
- DKK1 and TLE1 together suggest Wnt pathway involvement
- KRT6A, FUT4 - epithelial/differentiation
- LDLRAD3 - receptor
- RGS20 - signaling

Let me structure a rigorous response that:
1. Flags the obvious data quality issue
2. Focuses on the interpretable signal
3. Provides pathway-level interpretation
4. Suggests validation

I need to be honest about the limitations. The data appears to have significant technical artifacts that make the "top hits" uninterpretable. The real biological signal is in the lower-ranked genes with more reasonable HRs.

Let me think about the genuine biology:
- DKK1 (HR=1.48) - Dickkopf-1, secreted Wnt inhibitor. In LUAD, DKK1 has been reported as both tumor-promoting (via metabolic effects) and tumor-suppressive. High DKK1 in serum is associated with poor prognosis.
- TLE1 (HR=1.48) - Transducin-like enhancer of split 1, corepressor in Wnt and Notch signaling. Overexpression associated with poor prognosis in several cancers.
- PITX3 (HR=1.43) - Paired-like homeodomain transcription factor. Less well-characterized in LUAD.
- VAX1 (HR=1.33) - Ventral anterior homeobox 1. Mainly developmental.
- KRT6A (HR=1.39) - Keratin 6A, epithelial differentiation. High KRT6A has been linked to squamous features but also poor prognosis.
- FUT4 (HR=1.40) - Fucosyltransferase 4. Involved in selectin ligand synthesis, immune interactions.
- RGS20 (HR=1.35) - Regulator of G-protein signaling.
- CRNDE (HR=0.72) - lncRNA with various roles.
- RBMXP1 (HR=0.21) - pseudogene, protective.

The Wnt signaling theme is notable: DKK1 + TLE1 are both Wnt pathway components.

Other themes:
- Epithelial differentiation (KRT6A, possibly VAX1)
- Glycosylation/immune (FUT4)
- lncRNAs (multiple)

I'll structure my response to be intellectually honest about the data quality issues while extracting whatever biological signal can be recovered. I should NOT pretend the extreme HR genes are meaningful findings.

Let me write a comprehensive response following the requested structure.</think>

# Multidimensional Interpretation of Prognostic Transcriptomic Features in Lung Adenocarcinoma (LUAD)

## Preliminary Data Quality Assessment (Critical Context)

Before biological interpretation, the input dataset contains a striking technical feature that fundamentally shapes all downstream conclusions: **a large block of genes with hazard ratios effectively at numerical infinity (HR ≈ 5.18 × 10²¹, P = 0, FDR = 0).** These genes are almost exclusively:

- **Y-chromosome / testis-specific transcripts** (RBMY1F, RBMY2AP, FAM9A, CDY10P, USP9YP3, TTTY4C, TEX13A, VENTXP7)
- **Pseudogenes** (HMGN2P39, RAP1BP2, ATP5PBP2, RNY1P3, DRAXINP1, ETFRF1P1, MTND1P1, ATG4AP1, AMMECR1LP1, DIMT1P1, RBMXP1)
- **Unmapped / unassigned lncRNAs** (multiple "RP11-…", "LINC…", "CTD-…" loci; many "UNMAPPED_ENSEMBL_…" entries)

These patterns are **inconsistent with genuine prognostic biology** and almost certainly reflect sex-linked expression stratification artifacts: in LUAD cohorts with mixed sexes, Y-linked transcripts are either absent (in females) or highly expressed (in males), producing near-perfect event separation and numerical instability in Cox regression. Pseudogenes that mirror these loci behave identically.

**Therefore, these "top hits" should not be treated as biological prognostic features.** The interpretable biology lies in the tail of the table where HR values are finite and modest, with conventional effect sizes (HR roughly 0.2–1.5). All interpretations below are restricted to that subset.

---

## 1. Overall Biological Interpretation

The recoverable prognostic transcriptomic signal in this LUAD cohort is dominated by a relatively small set of coding genes and lncRNAs pointing toward three converging themes:

1. **Reactivation of developmental / Wnt-axis transcriptional programs** (DKK1, TLE1, VAX1, PITX3)
2. **Epithelial identity and differentiation remodeling** (KRT6A, FUT4, RHCG, LDLRAD3)
3. **Long non-coding RNA regulation with mixed prognostic polarity** (CRNDE protective; LINC01312, LINC02178, LINC01910, LINC00707, LINC02323, LINC02802, ITGB1-DT risk-elevating)

There is no signal consistent with classic LUAD prognostic biology such as immune checkpoint activation, cell-cycle programs, or epithelial–mesenchymal transition (EMT). Instead, the surviving signal is modest in magnitude and primarily involves tissue-patterning transcription factors and epithelial surface molecules. The strongest single protective coding-level signal (RBMXP1, HR = 0.21) is a **pseudogene of the RNA-binding RBMX**, and its biological interpretation is uncertain — it is more plausibly a marker of underlying expression of a nearby locus than an independent functional entity.

---

## 2. Core Biological Programs

### Program A — Reactivation of Wnt / Developmental Patterning Transcriptional Programs

- **Direction:** Risk-elevating (poor OS)
- **Major supporting genes:** DKK1 (HR 1.48, FDR 3.5 × 10⁻⁷), TLE1 (HR 1.48, FDR 2.5 × 10⁻⁵), VAX1 (HR 1.33, FDR 9.2 × 10⁻⁶), PITX3 (HR 1.43, FDR 3.5 × 10⁻¹¹), LDLRAD3 (HR 1.42, FDR 2.2 × 10⁻⁴)
- **Most appropriate pathway label:** Canonical Wnt signaling (KEGG hsa04310; Reactome "Signaling by Wnt"; Hallmark "Wnt/β-catenin signaling" — indirectly)
- **Why this program is supported:** DKK1 is a secreted Wnt antagonist whose paradoxically poor-prognosis association in LUAD has been reported as reflecting non-canonical, JNK-mediated or metabolic effects. TLE1 is a Groucho/TLE family transcriptional co-repressor that antagonizes Wnt-driven transcription and modulates Notch and Hippo outputs. VAX1 and PITX3 are paired-like homeodomain factors largely characterized in neural and pituitary development; their re-expression in carcinoma is a recognized "developmental reawakening" phenotype. LDLRAD3 has been linked to Wnt-pathway regulation in some contexts. Together these suggest a coordinated reactivation of an embryonic patterning axis that is unfavorable for survival.
- **Strength of evidence:** Moderate. Multiple independent genes converge on transcription-factor / developmental signaling biology, all with finite and biologically plausible HRs. The Wnt label is partially inferential — DKK1 and TLE1 are established Wnt components, but VAX1/PITX3 are linked by homology and expression context rather than direct pathway membership.
- **Major limitations:** No direct readouts of β-catenin target genes (AXIN2, MYC, CCND1) appear in the list; LDLRAD3's role in Wnt is not fully established; the dataset cannot distinguish canonical from non-canonical Wnt effects.

### Program B — Epithelial Identity, Keratinization, and Surface-Glycan Remodeling

- **Direction:** Risk-elevating
- **Major supporting genes:** KRT6A (HR 1.39, FDR 2.8 × 10⁻⁴), FUT4 (HR 1.40, FDR 2.9 × 10⁻⁴), RHCG (HR 1.29, FDR 4.7 × 10⁻⁴), CREG2 (HR 1.33, FDR 1.6 × 10⁻⁴)
- **Most appropriate pathway label:** Epithelial differentiation / glycosylation (Reactome "Keratinization"; GO "glycosylation"; Hallmark not directly applicable)
- **Why this program is supported:** KRT6A is a stress- and wound-responsive keratin associated with squamous-like differentiation states in LUAD, where it correlates with poor prognosis. FUT4 (fucosyltransferase 4) catalyzes α1,3-fucosylation of selectin ligands, modifying cell-surface glycans involved in adhesion and immune recognition. RHCG encodes an ammonium transporter expressed in epithelial tissues. CREG2 is a glycoprotein involved in epithelial homeostasis. The convergence on epithelial surface and differentiation machinery suggests that tumors with a more "epithelialized" or squamous-leaning transcriptomic state have worse outcomes in this cohort — possibly because the cohort is enriched for tumors losing the more favorable lepidic/acinar differentiation state.
- **Strength of evidence:** Moderate. Effect sizes are consistent (HR ~1.3–1.4), and the biology is coherent, but no other classic squamous markers (e.g., TP63, SOX2, DSG3) appear to corroborate the program within this dataset.
- **Major limitations:** Single-cohort observation; cannot exclude that KRT6A simply marks histological subtype (squamous-leaning LUAD variants) rather than an independent prognostic mechanism.

### Program C — lncRNA Regulatory Network with Mixed Polarity

- **Direction:** Mixed — predominantly risk-elevating, with one protective exception (CRNDE)
- **Major supporting genes:**
  - **Risk-elevating (HR 1.2–1.4):** LINC01312, LINC02178, LINC01910, LINC02323, LINC02802, LINC00707, ITGB1-DT, FAS-AS1, CTD-2066L21.1/2, RP11-1057N3.2, LOC105375754, RP11-96B2.1, RP11-438B23.2
  - **Protective (HR < 1):** CRNDE (HR 0.72, FDR 1.0 × 10⁻⁴)
- **Most appropriate pathway label:** No single pathway; collectively points to non-coding regulatory remodeling
- **Why this program is supported:** The sheer number of independent lncRNA loci reaching significance, with consistent modest risk-elevating effects, suggests systematic non-coding regulatory remodeling in tumors of poor prognosis. CRNDE is a well-characterized lncRNA whose context-dependent roles include chromatin regulation and metabolic effects; its protective direction here is noteworthy because CRNDE is more often reported as oncogenic in other cancers. FAS-AS1 (HR effectively infinity but classified as a finite-hazard lncRNA — see Data Quality note) is involved in regulating Fas-mediated apoptosis.
- **Strength of evidence:** Weak-to-moderate. Statistical signal is robust for individual loci, but functional interpretation is severely limited because most of these lncRNAs are not mechanistically characterized. CRNDE's protective direction is unusual and worth a separate hypothesis.
- **Major limitations:** Many are not mapped to standard gene symbols (RP11-, CTD-, AC-, AF-, LL22-, LOC-, UNMAPPED_ entries dominate the list). Without curated annotations, these cannot be confidently linked to pathways.

### Program D — G-Protein and Signaling Modulators

- **Direction:** Risk-elevating
- **Major supporting genes:** RGS20 (HR 1.35, FDR 5.8 × 10⁻⁴), RHOF (HR 1.40, FDR 4.0 × 10⁻⁴)
- **Most appropriate pathway label:** GPCR signaling / Rho GTPase regulation (Reactome "GPCR downstream signaling"; GO "regulation of G-protein coupled receptor protein signaling pathway")
- **Why this program is supported:** RGS20 is a regulator of G-protein signaling that accelerates GTP hydrolysis on Gα subunits; RHOF is an atypical Rho GTPase involved in actin dynamics. Both have been linked in published literature to migration / invasion phenotypes in carcinomas.
- **Strength of evidence:** Weak. Only two genes, modest effect sizes, and no pathway-level corroboration within the dataset.
- **Major limitations:** A two-gene program is borderline and could equally reflect noise.

### Program E — Apparent Risk-Associated Coding Signal of Uncertain Mechanism (RBMXP1)

- **Direction:** Protective (HR 0.21)
- **Major supporting genes:** RBMXP1 only
- **Why this program is included separately:** RBMXP1 is a processed pseudogene of RBMX (an X-linked RNA-binding protein involved in splicing). Its strong protective HR could either reflect a genuine RNA-splicing / genome-stability protective axis or, more parsimoniously, a confound with the parent RBMX locus expression, or an X-inactivation / sex-related artifact (RBMX escapes X-inactivation; copy-number effects on the X could produce strong HRs).
- **Strength of evidence:** Insufficient. Single gene, pseudogene locus, possible confound with sex chromosome biology.
- **Major limitations:** Cannot distinguish functional role from confounding locus effect.

---

## 3. Key Genes and Interaction Modules

I prioritize candidates with finite HRs, mechanistic plausibility, and possible clinical actionability. Genes with HR ≈ 10²¹ are excluded as artifacts.

| # | Gene | Direction (HR) | Core program | Proposed relationship type |
|---|------|-----------------|--------------|----------------------------|
| 1 | **DKK1** | Risk (1.48) | A — Wnt/development | Pathway co-membership (Wnt) with TLE1; secreted ligand with autocrine/paracrine role on tumor and stromal Wnt signaling |
| 2 | **TLE1** | Risk (1.48) | A — Wnt/development | Direct functional interaction with Wnt TCF/LEF transcription factors (co-repressor); regulatory interaction (transcriptional repression) |
| 3 | **PITX3** | Risk (1.43) | A — Wnt/development | Co-expression / pathway co-membership with VAX1, DKK1 (developmental TFs re-expressed in carcinoma); no direct physical interaction evidence in dataset |
| 4 | **VAX1** | Risk (1.33) | A — Wnt/development | Co-expression with other developmental TFs; putative relationship only |
| 5 | **KRT6A** | Risk (1.39) | B — Epithelial differentiation | Pathway co-membership (keratin family); putative relationship to squamous-leaning differentiation state |
| 6 | **FUT4** | Risk (1.40) | B — Surface glycan remodeling | Pathway co-membership (glycosylation); functional interaction with selectin ligands (immune cell adhesion) |
| 7 | **RGS20** | Risk (1.35) | D — G-protein signaling | Regulatory interaction (Gα GAP activity); no direct interaction evidence in dataset |
| 8 | **CRNDE** | Protective (0.72) | C — lncRNA network | Putative regulatory relationship with chromatin / metabolic pathways; no direct interaction evidence |
| 9 | **RBMXP1** | Protective (0.21) | E | Putative locus marker for RBMX expression; no physical interaction evidence |
| 10 | **LINC01312 / LINC00707** | Risk (1.36 / 1.32) | C — lncRNA network | Co-expression cluster of risk-elevating lncRNAs; no direct interaction evidence |

**Explicit interaction-type caveat:** No gene-gene relationship in this list should be interpreted as a direct physical interaction unless independently demonstrated. The strongest supported interaction is **DKK1 ↔ TLE1 ↔ Wnt pathway**, supported by established pathway-level evidence external to this dataset.

---

## 4. Validation Priorities

### Priority 1 — DKK1 as a Prognostic / Therapeutic Target in LUAD
- **Category:** Therapeutic target / Biomarker
- **Why prioritized:** DKK1 has a clinically actionable monoclonal antibody (DKN-01, BAY1839802) currently in oncology trials, and elevated serum DKK1 is an established marker in some LUAD cohorts. It is the most externally anchored candidate in this list.
- **Evidence from dataset:** Risk HR 1.48, FDR 3.5 × 10⁻⁷.
- **External evidence supporting:** DKK1 has been reported as both a Wnt antagonist (canonical) and a non-canonical, JNK-mediated metastasis promoter. DKN-01 is in Phase 1/2 trials in NSCLC subsets.
- **External evidence against:** Canonical Wnt inhibition by DKK1 would be expected to suppress tumor growth, conflicting with its risk role here — argues the effect is non-canonical.
- **Next step:** Validate in an independent LUAD cohort (TCGA-LUAD, CPTAC), test whether DKK1 protein in serum or tumor correlates with OS; assess whether the effect is enriched in non-canonical Wnt-high tumors.
- **Status:** **Supported hypothesis** (dataset + external trial context), but causal role unproven.

### Priority 2 — TLE1 + KRT6A Co-Signature as a Squamous-Leaning Poor-Prognosis Subtype
- **Category:** Biomarker / Mechanistic hypothesis
- **Why prioritized:** The convergence of TLE1 and KRT6A risk-elevating signals could mark an under-recognized LUAD subset with squamous-like differentiation features.
- **Evidence from dataset:** Both reach genome-wide FDR significance with consistent HRs ~1.4.
- **External evidence supporting:** TLE1 is a recognized IHC marker for synovial sarcoma; KRT6A marks squamous differentiation; squamous-leaning LUAD variants have distinct outcomes.
- **External evidence against:** Most LUAD prognostic signatures are dominated by immune, EMT, or proliferation programs, not by keratinization.
- **Next step:** IHC validation of TLE1 + KRT6A on a TMA; compare OS across TLE1⁺/KRT6A⁺ vs. double-negative tumors; adjust for histological subtype.
- **Status:** **Supported hypothesis** within this dataset; **exploratory hypothesis** overall.

### Priority 3 — CRNDE Protective Direction in LUAD (Paradox Resolution)
- **Category:** Mechanistic hypothesis
- **Why prioritized:** CRNDE is overwhelmingly reported as an oncogenic lncRNA in most cancers; a protective direction in LUAD would be a notable exception and warrants direct follow-up.
- **Evidence from dataset:** HR 0.72, FDR 1.0 × 10⁻⁴.
- **External evidence supporting:** Some reports show CRNDE's effect is context- and isoform-dependent; a small number of studies have suggested tumor-suppressive functions.
- **External evidence against:** Most literature supports an oncogenic role for CRNDE in colorectal, gastric, glioma, and other cancers.
- **Next step:** Inspect CRNDE splice isoforms in the cohort; test in LUAD cell lines whether CRNDE knockdown promotes or suppresses proliferation/migration.
- **Status:** **Exploratory hypothesis** — unusual direction requires careful validation before any functional claim.

### Priority 4 — Confounding / Composition Check for Sex-Linked Artifacts
- **Category:** Confounding or composition check
- **Why prioritized:** The dataset's top "hits" are dominated by Y-chromosome loci and pseudogenes, almost certainly reflecting sex stratification. Confirming this confound is essential before any publication-quality interpretation of the dataset.
- **Evidence from dataset:** Direct — Y-linked and pseudogene loci dominate the extreme-HR tier.
- **External evidence supporting:** Published literature consistently identifies sex as a prognostic factor in LUAD; female LUAD patients have generally better outcomes.
- **Next step:** Re-run Cox models adjusting for sex (and ideally stage, smoking, age); confirm that the finite-HR coding/lncRNA signal is independent of sex.
- **Status:** **Established evidence** that this confound exists; the analytical correction itself is a standard next step.

### Priority 5 — Validation of lncRNA Risk Cluster in Independent Cohorts
- **Category:** Biomarker
- **Why prioritized:** A coordinated risk-elevating lncRNA signature (LINC01312, LINC02178, LINC01910, LINC00707, etc.) is the most abundant signal class in the dataset and could form a clinically useful signature if validated.
- **Evidence from dataset:** Multiple loci with consistent HRs and genome-wide FDRs.
- **External evidence supporting:** lncRNA-based prognostic signatures have been published for many cancers including LUAD.
- **External evidence against:** Most individual lncRNAs in this class are not well characterized.
- **Next step:** Build a composite lncRNA risk score; test in TCGA-LUAD; assess incremental prognostic value over clinical covariates.
- **Status:** **Exploratory hypothesis**.

---

## 5. Evidence Grounding

| Claim | Evidence type | Independence |
|-------|---------------|--------------|
| DKK1 risk-elevating in LUAD | Direct (dataset) + disease-association + drug (DKN-01 trial context) + literature (NSCLC prognosis reports) | Multiple genuinely independent sources, though all converge on DKK1 biology |
| TLE1 risk-elevating | Direct (dataset) + pathway (Wnt/Notch co-repressor) + disease-association (synovial sarcoma marker; emerging LUAD data) | Partially independent |
| KRT6A risk-elevating | Direct (dataset) + pathway (keratinization) + tissue-specific expression evidence | Independent |
| Sex-linked artifact in top hits | Direct (dataset inspection) + genetic/clinical evidence (sex as LUAD prognostic factor) | Independent |
| CRNDE protective direction | Direct (dataset) + literature (context-dependent roles) | Weak; direction conflicts with broader literature |
| lncRNA cluster risk-elevating | Direct (dataset only) | **Insufficient evidence** — no external corroboration in input |

**No two evidence sources in this dataset are independent of the same underlying LUAD cohort**; replication in TCGA-LUAD or other cohorts is required before any claim should be considered robust.

---

## 6. Limitations and Alternative Explanologies

### Limitation 1 — Severe Sex-Linked Confound
The top of the result table is dominated by Y-chromosome loci and pseudogenes. Any interpretation that fails to first adjust for sex will be entirely confounded. **How to investigate:** Stratify by sex; re-fit Cox models with sex as a covariate; for the most extreme hits (RBMY1F, FAM9A, etc.) test whether the signal disappears after sex adjustment. If it does, the genes should be discarded as prognostic candidates in mixed-sex cohorts.

### Limitation 2 — Tumor Purity and Stromal-Admixture Effects
Genes such as KRT6A, DKK1, and FUT4 are expressed in epithelial or stromal compartments and can appear prognostic simply because they correlate with tumor purity or stromal fraction. **How to investigate:** Adjust for ESTIMATE or AbsCNSeq tumor-purity scores; test whether HRs persist in tumor-cell-only expression data (e.g., single-cell RNA-seq).

### Limitation 3 — Single-Cohort / Multiple-Testing Concerns
All findings come from a single discovery cohort. Although FDR is reported, the extreme values at the top of the table suggest the multiple-testing correction is overwhelmed by the sex-linked confound, not by true signal. Even among finite-HR genes, no replication is provided. **How to investigate:** Validate in TCGA-LUAD, CPTAC, or GSE cohorts.

### Limitation 4 — Lack of Canonical LUAD Prognostic Programs
The dataset does **not** recover expected prognostic programs: immune infiltration, EMT, cell-cycle, KRAS/MAPK targets, or STK11/LKB1 loss signatures. This absence is biologically implausible and suggests either (a) the analysis pipeline filtered them out, (b) the cohort is unusual, or (c) the analysis was driven by non-biological noise. **How to investigate:** Compare the gene-set enrichment profile of the cohort with published LUAD prognostic signatures.

### Limitation 5 — Association vs. Causation Ambiguity
All interpretations are observational. None of the proposed programs has been demonstrated to drive prognosis mechanistically. Particularly for DKK1, TLE1, and CRNDE, the causal direction (tumor → expression → outcome vs. expression → tumor behavior → outcome) is unknown. **How to investigate:** Functional perturbation in LUAD cell lines and xenografts; Mendelian randomization using *cis*-eQTL instruments.

---

## Bottom-Line Summary

The recoverable biological signal in this LUAD prognostic analysis is **modest in magnitude and concentrated in three themes**: (1) reactivation of developmental / Wnt-axis transcriptional programs (DKK1, TLE1, VAX1, PITX3), (2) epithelial differentiation and surface-glycan remodeling (KRT6A, FUT4), and (3) a non-coding RNA regulatory remodeling with predominantly risk-elevating polarity. The most clinically actionable candidate is **DKK1**, supported by independent trial context (DKN-01). The most striking dataset-level feature — extreme HRs dominated by Y-chromosome loci — is **almost certainly a sex-stratification artifact** and should be addressed analytically before any biological conclusion is drawn from the top of the table. No claim in this report should be considered established without independent cohort validation.
